Please assess the completion status of the following clinical trial:

Trial Title: Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of HPS~* Age ≥ 18 years~Exclusion Criteria:~* Intracardiac shunting~* Pregnancy~* Known hypersensitivity to bosentan~* Use of glyburide~* Use of cyclosporin A~* Elevation of aminotransferase level of \> 3 times the upper limit of normal~* Use of rifampicin~* Females of childbearing potential without use of adequate contraception~* Systolic blood pressure \< 85 mmHg~* Clinical relevant anemia~* HIV-infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo tablets twice daily for 3 months.
- bosentan (Type: ACTIVE_COMPARATOR): pts. will receive bosentan for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).